Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(14/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(14/week)
News
United States
(576/week)
Manufacturing
(398/week)
Energy
(304/week)
Technology
(413/week)
Environment
(238/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Glenmark Pharmaceuticals
Jun 20, 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
May 26, 2020
Glenmark to Commence New Phase 3 Clinical Trial on Combination of Two Anti-viral Drugs Favipiravir and Umifenovir in Hospitalized Patients of Moderate COVID-19 in India
May 12, 2020
Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India
Apr 29, 2020
Pipeline Insights for Seasonal Allergic Rhinitis, with Coverage of Allergy Therapeutics, Glenmark Pharmaceutical and VentiRx Pharmaceuticals
Feb 27, 2020
Hikma and Glenmark Pharmaceuticals Enter into Exclusive Licensing Agreement for Commercialising Ryaltris(TM) Seasonal Allergic Rhinitis Nasal Spray in the US
Feb 25, 2020
Neuraxpharm Reinforces Presence in Poland
May 02, 2019
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
Mar 01, 2019
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
Feb 25, 2019
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Feb 19, 2019
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Dec 14, 2018
Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018
Nov 15, 2018
Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris(TM) at the ACAAI Annual Scientific Meeting 2018
Nov 07, 2018
Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Oct 30, 2018
Glenmark Pharmaceuticals Celebrates the Inauguration of its U.S. Manufacturing Site in Monroe, North Carolina
Sep 12, 2018
Mitra Biotech Announces Partnership with Glenmark Pharmaceuticals to Provide Clinically Relevant Translational Platform Supporting Development of Immuno-Oncology Portfolio
Aug 07, 2018
Glenmark Pharmaceuticals Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris(TM) for Patients with Seasonal Allergic Rhinitis
Jun 18, 2018
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina
May 21, 2018
Glenmark Pharmaceuticals Announces the Company's First New Drug Application for Ryaltris(TM) for Patients with Seasonal Allergic Rhinitis
May 17, 2018
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
Apr 16, 2018
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
Page 1
››
Latest News
Apr 25, 2024
Aquidneck Island Productions, LLC, Under the Esteemed Production of Scott Wiper, Proudly Presents: FLYNN
Apr 25, 2024
Nortech Systems Incorporated to Report First Quarter 2024 Financial Results and Hold a Conference Call on May...
Apr 25, 2024
International Seaways to Announce First Quarter 2024 Results on May 8, 2024
Apr 25, 2024
Ohmium Partners with Tata Projects to Advance Green Hydrogen Initiatives in India
Apr 25, 2024
Blue Bird to Report Fiscal 2024 Second Quarter Results on May 8, 2024
Apr 25, 2024
Mercedes-Benz AG Hosts Event to Test CCC Digital Key Specification with UWB and Bluetooth LE
Apr 25, 2024
Horizon Realty Advisors Unveils The Edison: A Sustainable Luxury Apartment Community in Reno
Apr 25, 2024
Littelfuse to Present at Upcoming Investor Conferences
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events